biotech IPO Archives -

Stock brokers looking at computer screens, trading online.

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease

Calliditas hits $90m jackpot as biotech IPO craze continues

https://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/

News/ News/ News/ Oncology/ R&D

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Phil Taylor antibody, antibody-drug conjugate, biotech IPO, bispecific antibody, Genmab, partnering 0 Comment

Genmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

https://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/

R&D/ Views & Analysis/ Views and analysis

Calliditas pushing on with kidney disease drug after IPO success

Richard Staines biotech IPO, kidney disease 0 Comment

Calliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it

Calliditas pushing on with kidney disease drug after IPO success

https://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/

Articles/ R&D/ UK & Europe/ Views and analysis

Circassia a cautionary tale for UK biotech, says Grainger

Andrew McConaghie biotech IPO, Circassia, David Grainger, Medicxi, UK biotech 0 Comment

The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.

Circassia a cautionary tale for UK biotech, says Grainger

https://pharmaphorum.com/views-and-analysis/circassia-cautionary-tale-uk-biotech-says-grainger/

News/ UK & Europe/ US

Are biotech IPOs back in fashion?

Richard Staines Biotech, biotech IPO, cancer, finance, IPO, Ovid, Rare diseases, Takeda, Verona Pharma 0 Comment

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months

Are biotech IPOs back in fashion?

https://pharmaphorum.com/news/biotech-ipos-coming-back-fashion/

News/ US

Cancer biotech BeyondSpring hit by weak IPO

Richard Staines BeyondSpring, biotech IPO, cancer, lung cancer 0 Comment

Hoping for $100m, biotech raises under $3.5 million on stock market

Cancer biotech BeyondSpring hit by weak IPO

https://pharmaphorum.com/news/cancer-drug-firm-beyondspring-downsizes-ipo/

Cancer/ News/ US

Jounce set to make first biotech IPO of 2017

Andrew McConaghie biotech IPO, IPO, Jounce 0 Comment

Massachusetts-based company will test the waters for biotech sector

Jounce set to make first biotech IPO of 2017

https://pharmaphorum.com/news/jounce-gets-early-lead-2017-biotech-ipos/

News

Circassia leads UK biotech funding success

Andrew McConaghie allergies, biotech IPO, Circassia, IPO, UK biotech 0 Comment

Three separate fund-raising rounds – headed by Circassia’s £275 million placing and open offer – give a further

Circassia leads UK biotech funding success

https://pharmaphorum.com/news/circassia-leads-uk-biotech-funding-success/

Trending

biotech IPO

Login